98%
921
2 minutes
20
Objective: To compare oral pregabalin with oral sertraline for treatment of uraemic pruritus.
Study Design: Randomised controlled trial. Place and Duration of the Study: Department of Nephrology, Pak Emirates Military Hospital Rawalpindi, Pakistan, from October 2023 to January 2024.
Methodology: Patients with end-stage renal disease having pruritus for at least 6 weeks were included. Exclusion criteria comprised other dermatological or systemic diseases associated with pruritus, mental health issues, thrice-a-week haemodialysis schedule, and use of other treatments for uraemic pruritus. They were randomised to receive either pregabalin 75mg daily or sertraline 50mg daily for six weeks using computer-generated sequences. The Urdu version of the 5-D Itch scale was used to document the severity of pruritus at the baseline and at the end of therapy. Side effects to the treatment were also monitored.
Results: There were 8 (16.67%) females and 40 (83.33%) males, with a mean age of 52.19 ± 12.19 years. The baseline 5-D Itch scale scores were equal in both groups. Mean improvement in 5-D Itch scale scores was 3.75 ± 1.26 and 2.08 ± 1.18 with pregabalin and sertraline, respectively (p <0.001). Side effects were reported by 2 (8.33%) patients on pregabalin and none using sertraline (p = 0.489).
Conclusion: Pregabalin was found to be more effective than sertraline in treating uraemic pruritus, though with a statistically insignificant trend towards a higher frequency of side effects.
Key Words: Chronic renal failure, Pruritus, Renal dialysis, Selective serotonin reuptake inhibitors, Uraemia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.29271/jcpsp.2024.09.1061 | DOI Listing |
J Formos Med Assoc
August 2025
Department of Pediatrics, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; Department of Pediatrics, Taoyuan Armed Forces General Hospital, Taoyuan City, Taiwan. Electronic address:
Objective: Hemodialysis patients frequently exhibit altered gut microbiota and elevated indoxyl sulfate (IS) levels, a uremic toxin linked to negative health outcomes. This study explores how probiotic supplementation may be associated with changes in uremic toxins and sleep quality in hemodialysis patients through its relationship with gut microbiota.
Design And Methods: This open-label, randomized cohort study involved 80 hemodialysis patients with poor sleep quality, assessed by the Pittsburgh Sleep Quality Index (PSQI) Global Score.
Adv Mind Body Med
August 2025
Nursing, MSc Nursing (Mental Health Nursing), Master in Arts (MA Sociology), Postgraduate Diploma in Hospital Administration (PGDHA), Post Graduate Certificate in Diabetes Mellitus (PGCDM), Diploma in Counselling Psychology, PhD (Mental Health Nursing), Deputy Director and Professor, Symbiosis Colle
Background: Neurodermatitis significantly impairs quality of life due to the chronic itch-scratch cycle driven by compulsive excoriation behavior.
Objective: This study evaluated the effectiveness of a tailored therapeutic regimen in reducing excoriation behavior and improving patient outcomes.
Research Design: Quasi-experimental study conducted over six weeks.
Liver Int
September 2025
Gilead Sciences, Foster City, California, USA.
Background & Aims: This US-based study assessed the impact of pruritus on health-related quality of life (HRQoL) and treatment experiences of people with primary biliary cholangitis (PBC).
Methods: Patients with PBC were recruited from a physician panel and patient advocacy group. Participants were grouped by the Pruritus Numerical Rating Scale (NRS): No/Mild Pruritus (NMP, NRS < 4) and Moderate/Severe Pruritus (MSP, NRS ≥ 4).
BMJ
August 2025
Kidney Disease Centre, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang, China
Objective: To evaluate the efficacy and safety of anrikefon (formerly known as HSK21542), a novel selective peripherally restricted kappa opioid receptor agonist, in patients with chronic kidney disease associated pruritus.
Design: Multicentre, double blind, randomised placebo controlled phase 3 trial.
Setting: 50 centres in China, June 2022 to June 2024.
Background: Cholestatic pruritus is common in primary biliary cholangitis (PBC), often leading to sleep disturbances and substantially impairing health-related quality of life (HRQoL). Fatigue, also frequent in PBC, can be exacerbated by sleep interference due to nighttime pruritus. Quantitative numerical rating scales (NRS) are appropriate for assessing unidimensional patient-reported outcome (PRO) concepts and are easily interpreted.
View Article and Find Full Text PDF